




Searching News Database: cannabinoid
HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 5 May 2021
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
HSMN NewsFeed - 31 Jan 2018
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
HSMN NewsFeed - 2 Nov 2017
Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer
Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer
HSMN NewsFeed - 18 Sep 2017
Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer
Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer
HSMN NewsFeed - 5 Apr 2017
Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology
Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology
HSMN NewsFeed - 23 Aug 2016
Kalytera Therapeutics Appoints Dr. Andrew Salzman as Chief Medical Officer
Kalytera Therapeutics Appoints Dr. Andrew Salzman as Chief Medical Officer
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
HSMN NewsFeed - 5 Jan 2012
INSYS Therapeutics Announces FDA Approval of SUBSYS(R) Fentanyl Sublingual Spray
INSYS Therapeutics Announces FDA Approval of SUBSYS(R) Fentanyl Sublingual Spray
HSMN NewsFeed - 5 Dec 2011
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team
HSMN NewsFeed - 30 Mar 2011
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
HSMN NewsFeed - 21 Jul 2010
Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
HSMN NewsFeed - 11 Jun 2008
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
HSMN NewsFeed - 18 Dec 2007
Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
HSMN NewsFeed - 15 Feb 2007
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
HSMN NewsFeed - 19 Jan 2007
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Additional items found! 18

Members Archive contains
18 additional stories matching:
cannabinoid
(Password required)
cannabinoid
(Password required)